Contact IMV

IMV Executive Assistant

email: virology@umn.edu

tel. (612) 624-1926

fax. (612) 625-1108

 

18-242 Moos Tower
515 Delaware St. SE
Minneapolis, MN 55455

General Questions:

virology@umn.edu

Louis Mansky,
Director, Institute for Molecular Virology, Professor

Diag/Biological Sciences, School of Dentistry
Microbiology, Medical School

Phone: (612) 626-5525

Email: mansky@umn.edu

Education

B.S., Purdue University

Ph.D., Iowa State University

Postdoctoral Research: Laboratory of Howard M Temin, University of Wisconsin-Madison

Research Interests

Cell and molecular biology of HIV and HTLV; Antiviral drug target identification; Antiviral drug resistance; HIV genetic variation, evolution and population genetics; Viral quasispecies; Virus assembly; Evolution of emerging viruses; Paleovirology.

The study of retroviruses over the past three decades has led to some of the most important discoveries in biomedical research, and has laid the foundation for biotechnology, cancer research, AIDS research, and human gene therapy. The discovery of reverse transcriptase helped to create the biotechnology industry, the discovery of oncogenes helped to advance our understanding of the genetic basis of cancer, and the discovery of retroviruses in higher animals led to the discovery of human retroviruses that cause cancer (HTLV-1) and AIDS (HIV-1). The creation of retroviral vectors and retrovirus helper cell lines helped to establish the field of gene therapy.

Retroviruses are relatively simple viruses that encode from three to ten genes, but are unusual in that they undergo a step in their life cycle called reverse transcription, which is the synthesis of double-stranded DNA from single-stranded RNA. We are exploring the accuracy of this process in HIV-1 replication and how it influences not only the evolution of HIV-1 variants that are resistant to anti-HIV-1 drugs, but also how it influences the development of an effective AIDS vaccine. We are also exploring how the APOBEC3 proteins impact HIV evolution and drug resistance. A long-term goal of our efforts is to define the molecular determinants for HIV-1 mutation in order to 1) manipulate HIV-1 evolution and improve the efficacy of anti-HIV-1 drugs, and 2) provide the basis for new intervention strategies.

Central steps in the retrovirus life cycle include the recognition of the genomic RNA by the Gag protein, trafficking of Gag and viral RNA to the plasma membrane, Gag oligomerization, and ultimately the biogenesis of virus particles. The details behind how Gag and RNA trafficking as well as virus particle biogenesis occurs is currently being investigated via collaboration by employing highly sophisticated biophysical approaches - including fluorescence spectroscopy methodologies that have single molecule resolution as well as cryoelectron microscopy/tomography. A long term goal of these studies is to develop a better understanding of the detailed steps of Gag oligomerization, viral RNA packaging, and virus biogenesis/virus structure. Such information will ultimately be useful for the discovery of new targets for the rational design of antiviral drugs.

Metabolic disorders associated with highly active antiretroviral therapy (HAART) are becoming increasingly important in the chronically HIV-infected population that has access to therapy.  Clinical observations have revealed a strong correlation between bone density loss in HIV-infected individuals during HAART, particularly in conjunction with the antiretroviral drug tenofovir - a nucleotide analog that inhibits HIV reverse transcriptase.  We are working collaboratively with bone biologists and AIDS clinicians to investigate how HIV-1 infection and tenofovir can cause bone mineral density loss.

Selected Recent Publications 

  • Fogarty KH, Berk S, Grigsby IF, Chen Y, Mansky LM, Mueller JD. 2013. Interrelationship between cytoplasmic retroviral Gag concentration and Gag-membrane association. Journal of Molecular Biology. Epub ahead of print.
  • Sun M, Grigsby IF, Gorelick RJ, Mansky LM, Musier-Forsyth K. 2013. Retrovirus-specific differences in matrix and nucleocapsid protein-nucleic acid interactions: implications for genomic RNA packaging. Journal of Virology. Epub ahead of print.
  • Dapp MJ, Bonnac, L, Patterson, SE, Mansky, LM. 2013. Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1. Journal of Virology. Epub ahead of print.
  • Clouser, CL, Bonnac, L, Mansky, LM, Patterson, SE. 2013. Characterization of permeability, stability, and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs. Antiviral Chemistry & Chemotherapy. Epub ahead of print.
  • Rawson, JM, Heineman, RH, Beach, LB, Martin, JL, Schnettler, EK, Dapp, MJ, Patterson, SE, Mansky, LM. 2013. 5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorganic and Medicinal Chemistry. 21:7222-7228.
  • Bonnac, LF, Mansky, LM, Patterson, SE. 2013. Structure-activity relationships and design of viral mutagens and application to lethal mutagenesis. J. Med. Chem. Epub ahead of print
  • Holtz CM, Sadler, HA, Mansky, LM. 2013. APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure. Nucleic Acids Research 41:6139-6148.
  • Holtz CM, Mansky LM. 2013. Variation of HIV-1 mutation spectra among cell types. J Virol. 87:5296-5299.
  • Dapp MJ, Patterson, SE, Mansky, LM. 2012. Back to the future: revisiting HIV-1 lethal mutagenesis. Trends in Microbiology. 21:56-62.
  • Dapp MJ, Heineman, RH, Mansky LM. 2012. Interrelationship between HIV-1 fitness and mutation rate. J Mol Biol. 425:41-53.
  • Clouser, CL, Chauhan, J, Bess, MA, Oploo, JL, Zhou, D, Dimick-Gray, S, Mansky, LM, Patterson, SE. 2012. Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett. 22:6642-6646.
  • Dapp, MJ, Holtz, CM, Mansky LM. 2012. Concomitant lethal mutagenesis of human immunodeficiency virus type 1. J Mol Biol. 419:158-170.
  • Clouser CL, Holtz CM, Mullet M, Crankshaw DL, Briggs JE, O’Sullivan MG, Patterson SE, Mansky LM. 2012.  Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1. Antimicrobial Agents and Chemotherapy. 56:1942-1948.
  • Greggs, WM 3rd, Clouser CL, Patterson SE, Mansky LM. 2012.  Discovery of drugs that possess activity against feline leukemia virus. Journal of General Virology 93:900-905.

  • Guenzel CA, Hérate C, Le Rouzic E, Maidou-Peindara P, Sadler HA, Rouyez MC, Mansky LM, Benichou S.  2012.  Recruitment of the nuclear form of uracil DNA glycosylase into virus particles participates in the full infectivity of HIV-1.  J Virol. 86:2533-44.

  • Fogarty, K.H., Zhang, W., Grigby, I.F., Johnson, J.L., Chen, Y., Mueller, J.D., and L.M. Mansky.  2011.  New insights into HTLV-1 particle structure, assembly and Gag-Gag interactions in living cells.  Viruses 3:770-793.

  • Wu K, Chen L, Peng G, Zhou W, Pennell CA, Mansky LM, Geraghty RJ, Li F.  2011.  A virus-binding hot spot on human angiotensin-converting enzyme 2 is critical for binding of two different coronaviruses J Virol. 2011  85:5331-7.

  • Fogarty, K.H., Johnson, J.L., Grigsby, I.F., MacDonald, P.J., Smith, E.M., Chen, Y., Rawson, J.M., Mansky, L.M., and J.D. Mueller, J.D. 2011. Characterization of cytoplasmic Gag-Gag interactions by dual-color z-scan fluorescence fluctuation spectroscopy. Biophysical Journal. 100:1587-95.

  • Greggs WM 3rd, Clouser CL, Patterson SE, Mansky LM.  2011. Broadening the use of antiretroviral therapy:  the case for feline leukemia virus.  Therapeutics and Clinical Risk Management.  7:115-22.
  • Clouser, C.L., Holtz, C.M., Mullet, M., Crankshaw, D.L., Briggs, J.E., Chauhan, J., VanHoutan, I.M., Patterson, S.E., and L.M. Mansky.  2011.  Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.  PLoS One  6:e15840
  • Ni, Z., Knorr, D.A., Clouser, C.L., Hexum, M.K., Southern, P., Mansky, L.M., Park, I.-H., and D.S. Kaufman. 2011.  Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity utilizing diverse cellular mechanisms.  Journal of Virology 85:43-50.
  • Dorr, C.R., Yemets, S., Kokomitsyna, O., Krasutsky, P., and L.M. Mansky. 2011. Triterpene derivatives that inhibit human immunodeficiency virus type 1 replication. Bioorganic and Medicinal Chemistry Letters 21:542-545.
  • Grigsby, I.F., Zhang, W., Johnson, J.L., Fogarty, K.H., Chen, Y., Rawson, J.M., Crosby, A.J., Mueller, J.D., and L.M. Mansky. 2010.  Biophysical analysis of HTLV-1 particles reveals novel insights into particle morphology and Gag stochiometry.  Retrovirology  7:75
  • Sanjuan, R., Nebot, M.R., Chirico, N., Mansky, L.M., and R. Belshaw.  Viral mutation rates.  Journal of Virology. 84:9733-9748.
  • Clouser, C.L., Patterson, S.E., and L.M. Mansky. 2010. Exploiting drug repositioning for the discovery of a novel HIV combination therapy.  Journal of Virology  84:9301-9309.
  • Sadler, H.A., Stenglein, M.D., Harris, R.S., and L.M. Mansky. 2010.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.  Jounral of Virology 84:7396-7404.
  • Grigsby, I.F., Pham, L., Mansky, L.M., Gopalakrishnan, R., Carlson, A. and K.C. Mansky, K.C. 2010.  Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochemical and Biophysical Research Communications 394:48-53.
  • Grigsby, I.F., Pham, L., Gopalakrishnan, R., Mansky, L.M., and K.C. Mansky.  2010.  Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts.  Biochemical and Biophysical Research Communications  391:1324-1329.
  • Grigsby, I.F., Pham, L., Mansky, L.M., Gopalakrishnan, R., and K.C. Mansky. 2009.  Tenofovir-associated bone density loss.  Therapeutics and Clinical Risk Management 6:41-47.
  • Dapp, M.D., Clouser, C.L., Patterson, S.E. and L.M. Mansky. 2009.  5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1.  Journal of Virology 83:11950-58.
  • Chen, Y. Wu, B., Musier-Forsyth, K., Mansky, L.M., and J.D. Mueller. 2009.  Fluorescence fluctuation spectroscopy on viral-like particles reveals variable Gag stoichiometry.  Biophysics Journal 96:1961:1969.
  • Nishiguichi, M.K., Hirsch, A.M., deVinney, R., Vendantam, G., Riley, M.A., and L.M. Mansky.  2008. Deciphering evolutionary mechanisms between mutualistic and pathogenic symbioses. Life and Environment  58: 87-106.
  • Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., Brown W.L., Mansky L.M., Gorelick R.J., Harris R.S., Engelman A., Pathak V.K. 2007. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. Journal of Virology 81:7099-7110.
  • Hache G., Mansky L.M., and Harris R.S. 2006. Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev. 8:148-57.
  • Dorweiler, I.J., Ruone, S.J., Wang, H., Burry, R.W., and L.M. Mansky. 2006. Role of the human T-cell leukemia virus type 1 PTAP motif in Gag targeting and particle release. Journal of Virology 80:3634-3643.
  • Chen, R., Yokohama M., Sato H., Reilly C. Mansky, LM. 2005. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies, Journal of Virology 79:12045-57.
  • Jewell, N.A. and L.M. Mansky. 2005. Packaging of heterologous RNAs by a minimal bovine leukemia virus RNA packaging signal into virus particles. Archives of Virology 150:1161-73.
  • Jewell, N.A. and L.M. Mansky. 2005. Construction and characterization of deltaretrovirus indicator cell lines. Journal of Virological Methods 123:17-24.
  • Chen, R., Quinones-Mateu, M.E., and L.M. Mansky. 2005. HIV-1 mutagenesis during antiretroviral therapy: implications for successful drug treatment. Frontiers in Biosciences 10:743-750.
  • Chen, R., Quinones-Mateu, M.E., and L.M. Mansky. 2004. Drug resistance, virus fitness and HIV-1 mutagenesis. Current Pharmaceutical Design 10:4065-4070.
  • Spidel, J.L., Craven, R.C., Wilson, C.B., Patnaik, A., Wang, H., Mansky, L.M., and J.W. Wills. 2004. Lysines close to the Rous sarcoma virus late domain critical for budding. Journal of Virology 78:10606-10616.
  • Chen, R., LeRouzic, E. Kearney, J.A., Mansky, L.M., and S. Benichou. 2004. Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J. Biol. Chem. 279:28419-25.
  • Weiss, K.K., Chen, R., Lee, K., Bambara, R.A., Mansky, L.M., and B. Kim. 2004. A role for dNTP binding of human immunodeficiency virus type 1 reverse transcriptase in viral mutagenesis. Biochemistry 43:4490-4500.
  • Wang, H., N. M. Machesky, and L. M. Mansky. 2004. Both the PPPY and PTAP motifs in the human T-cell leukemia virus type 1 Gag protein are required for particle release. Journal of Virology 78:1503-1512.

Other Links

 

 

Featured News & Events

'Wisc-e-sota', a Joint UMN-UW Virology Training Grant Symposium was first held on Friday, Sepbember 20th, 2013 at the Uniiversity of Wisconsin-La Crosse, Cartwright Center. This was the inaugural collaborative symposium of the NIH T32-supported virology training programs at the University of Wisconsin-Madison and the University of Minnesota-Twin Cities. Talks and poster sessions were presented by students, postdocs and faculty. The second UMN-UW Virology Training Grant Symposium will be held in the Fall 2014. Details to follow.

The 2014 IMV Symposium will be held on May 12, 2014 and Mark Denison (Vanderbilt) and Bert Semler (UC-Irvine) will be the Keynote Speakers. Click on the link below to register and submit abstracts.

About the IMV icon

Read about bacteriophage phi 29 and why it matters.

IMV Timeline

Explore nearly a century's worth of discovery in the field of virology at the University of Minnesota.

TWiV

"This Week in Virology" from professor Vincent Racaniello.